Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. CRISPR Therapeutics AG shares valued at $1,449,628 were sold by Kulkarni Samarth on Mar 15 ’24. At $72.48 per share, Kulkarni Samarth sold 20,000 shares. The insider’s holdings dropped to 208,122 shares worth approximately $14.6 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Prasad Raju sold 3,524 shares, netting a total of over 256,160 in proceeds. Following the sale of shares at $72.69 each, the insider now holds 6,476 shares.
Before that, Kulkarni Samarth had sold 4,583 shares from its account. In a trade valued at $341,159, the Chief Executive Officer traded CRISPR Therapeutics AG shares for $74.44 each. Upon closing the transaction, the insider’s holdings decreased to 4,583 shares, worth approximately $14.6 million.
As published in their initiating research note from Wolfe Research on February 15, 2024, CRISPR Therapeutics AG [CRSP] has been a Peer perform. Analysts at TD Cowen downgraded the stock from ‘”a Market perform”‘ to ‘”an Underperform”‘ outlook in a report released in mid December. As of October 17, 2023, Cantor Fitzgerald has decreased its “an Overweight” rating to a “Neutral” for CRSP. Earlier on September 27, 2023, Mizuho initiated its rating. Their recommendation was “a Buy” for CRSP stock.
Analyzing CRSP Stock Performance
During the last five days, there has been a drop of approximately -3.81%. Over the course of the year, CRISPR Therapeutics AG shares have jumped approximately 12.08%. Shares of the company reached a 52-week high of $91.10 on 02/22/24 and a 52-week low of $58.29 on 01/08/24. A 50-day SMA is recorded $73.33, while a 200-day SMA reached $59.23. Nevertheless, trading volume fell to 1.34 million shares from 0.91 million shares the previous day.
Support And Resistance Levels for CRISPR Therapeutics AG (CRSP)
According to the 24-hour chart, there is a support level at 68.85, which, if violated, would cause prices to drop to 67.53. In the upper region, resistance lies at 71.51. The next price resistance is at 72.85. RSI (Relative Strength Index) is 39.07 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.51, which suggests the price will decrease in the coming days. Percent R is at 90.04%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
Is CRISPR Therapeutics AG subject to short interest?
Stocks of CRISPR Therapeutics AG saw a sharp steep in short interest on Mar 15, 2024 dropping by -0.15 million shares to 14.72 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 14.87 million shares. A decline of -1.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.82 of the overall float, the days-to-cover ratio (short ratio) decline to 6.82.
